All News
Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis
Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.
Read Article
Baricitinib Efficacy in Alopecia Areata
The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder.
Read Article
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow Live is Coming to Town (3.11.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
Read Article
Drug Survival Differences in RA, PsA, SpA and PsO
Drug survival may be the best measure of efficacy and safety. A new study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.
Read Article
COSMOS Study - Guselkumab Efficacy at 1 Year in Psoriatic Arthritis
Guselkumab, an IL-2319-subunit antibody, was studied in active psoriatic arthritis (PsA) patients who had a previously inadequate response (IR) to tumour necrosis factor inhibitors (TNFi) and after 1 year was shown to significantly improved joint and skin manifestations and physical function.
Read Article
Two Year Guselkumab Benefits in Psoriatic Arthritis
Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.
Read Article
Hand OA and Heroes in Rheumatology (2.11.2022)
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
An Ounce of Prevention (2.4.2022)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
The Overpricing of Drugs (1.14.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
Read Article
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.
Read Article
Spesolimab, an IL-36 Blocker, in Pustular Psoriasis
The NEJM has published the results of a phase 2 randomized trial showing that the use of an interleukin-36 receptor inhibitor, spesolimab, resulted in rapid improvement of generalized pustular psoriasis (at 1 week), but that adverse events and infections were of concern with 12 weeks of foll
Read Article
Best of 2021: FDA Approves Anifrolumab in SLE
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Read Article